ArticleNeurosurgical review2025
Association of dexamethasone with outcomes in aneurysmal subarachnoid hemorrhage: A Propensity-Matched analysis from a Multi-Institutional database.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of dexamethasone in patients with aneurysmal subarachnoid hemorrhage (aSAH) remains controversial. The response to dexamethasone may vary depending on the management strategies between endovascular treatment and microsurgical clipping. We used the TriNetX database, a global network of healthcare organizations, to identify patients with aSAH. Patients were grouped based on whether they received endovascular treatment or microsurgical clipping. In each group, outcomes were analyzed based on dexamethasone usage. Odds ratios (ORs) for each outcome were calculated through propensity score-matched analysis. There were 11,078 patients in the endovascular group and 3,885 patients in the microsurgical clipping group. Dexamethasone use was associated with improved survival in patients who received endovascular treatment in both short- and mid-term outcomes (OR 0.35, 95% confidence interval (CI) 0.26-0.46 at 30 days; OR 0.42, 95% CI 0.33-0.53 at 6 months). However, no survival advantage was observed in patients who underwent microsurgical clipping. There were no significant differences in vasospasm or shunt requirements between patients who received dexamethasone and those who did not, irrespective of treatment type; however, patients who received dexamethasone had a lower rate of fever in both groups. aSAH is a challenging disease, and our study indicates that dexamethasone is associated with improved overall survival in patients who underwent endovascular treatment. Reconsidering the role of dexamethasone, with attention to treatment modality, may provide new insights and potentially different outcomes in aSAH management.
Indexed as
Identifiers
41152643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.